Drug Database
Back to search

Germany· DE-A57-1e18b9b3a2efb167

Holoxan

A ifosfamide product containing ifosfamide, registered in Germany by Baxter Deutschland Gmbh. The same ATC class is registered in 15 of our 19 countries.

ATC L01AA06

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedHoloxanATCL01AA06REGISTER NO.DE-A57-1e18b9b3a2efb1…PACKS LISTED0CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ifosfamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ifosfamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 9 of them publish a price we can compare per daily dose
Search ifosfamide products by name

Ifosfamide · ATC L01AA06

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ifosfamide costs, country by country.

Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ifosfamide · price per daily dose (0.7 g)

USD · FX 28 Sept 2026

  • CH Switzerland$52.67
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

EMA Article 57 (European Union)
Active substance
Ifosfamide
Manufacturer
Baxter Deutschland Gmbh
Country
Germany (DE)
ATC code
L01AA06
ATC class
Ifosfamide
Defined daily dose
0.7 g, P
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

514 interactions on record for ifosfamide.

Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ifosfamide against other medicinesHow interaction checks work

Ifosfamide · interactions on record

514 records

  • 41 severe
  • 385 moderate
  • 16 minor
  • 72 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • CidofovirJ05AB12severe
  • ThiotepaL01AC01severe
  • CladribineL01BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ifosfamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ifosfamide products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Holoxan
  • Belgium · Holoxan
  • Bulgaria · Холоксан
  • Czechia · Holoxan
  • Denmark · Holoxan
  • Estonia · Holoxan
  • Spain · Tronoxal
  • Finland · Holoxan
  • France · Holoxan, Ifosfamide Eg
  • United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
  • Greece · Holoxan
  • Croatia · Holoxan
  • Hungary · Holoxan
  • Ireland · Mitoxana
  • Iceland · Holoxan
  • Italy · Holoxan
  • Lithuania · Holoxan
  • Luxembourg · Holoxan
  • Latvia · Holoxan
  • Malta · Mitoxana
  • Netherlands · Holoxan
  • Norway · Holoxan
  • Poland · Holoxan
  • Portugal · Holoxan
  • Romania · Holoxan
  • Sweden · Holoxan
  • Slovenia · Holoxan
  • Slovakia · Holoxan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eded107b-659d-477c-90d5-c2d69f93882e
GET /v1/drugs/eded107b-659d-477c-90d5-c2d69f93882e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Ifosfamide",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}
API referenceMCP serverPlans

See everything about ifosfamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console